drugset / Trial / NCT01847092

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

NCT01847092

Phase 2 Completed 154 enrolled Ardelyx AstraZeneca · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.

Timeline

Start
2013-05
Primary completion
2015-03
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tenapanor Small molecule 5 mg Oral
Comparator Tenapanor Small molecule 15 mg Oral
Comparator Tenapanor Small molecule 30 mg Oral
Comparator Tenapanor Small molecule 60 mg Oral